BRPI0809346A2 - Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos - Google Patents

Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos

Info

Publication number
BRPI0809346A2
BRPI0809346A2 BRPI0809346-6A2A BRPI0809346A BRPI0809346A2 BR PI0809346 A2 BRPI0809346 A2 BR PI0809346A2 BR PI0809346 A BRPI0809346 A BR PI0809346A BR PI0809346 A2 BRPI0809346 A2 BR PI0809346A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
same
composition containing
derivative compounds
substituted imidazopyridine
Prior art date
Application number
BRPI0809346-6A2A
Other languages
English (en)
Inventor
Guenther Metz
Achim Feurer
Sonja Nordhoff
Christian Rummey
Ulrich Abel
Holger Deppe
Inge Ott
Michael Soeberdt
Barbara Hoffmann-Enger
Philipp Weyermann
Herve Siendt
Miroslav Terinek
Marco Henneboehle
Holger Herzner
Cesare Mondadori
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Publication of BRPI0809346A2 publication Critical patent/BRPI0809346A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0809346-6A2A 2007-03-28 2008-03-28 Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos BRPI0809346A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92050007P 2007-03-28 2007-03-28
EP07006422A EP1974729A1 (en) 2007-03-28 2007-03-28 Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
PCT/EP2008/002498 WO2008116665A1 (en) 2007-03-28 2008-03-28 Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0809346A2 true BRPI0809346A2 (pt) 2014-10-07

Family

ID=38335635

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809346-6A2A BRPI0809346A2 (pt) 2007-03-28 2008-03-28 Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos

Country Status (13)

Country Link
US (1) US8236818B2 (pt)
EP (2) EP1974729A1 (pt)
JP (1) JP2010522224A (pt)
KR (1) KR101128140B1 (pt)
CN (1) CN101663301B (pt)
AU (1) AU2008231977B2 (pt)
BR (1) BRPI0809346A2 (pt)
CA (1) CA2682329C (pt)
IL (1) IL200804A0 (pt)
MX (1) MX2009010429A (pt)
NZ (1) NZ579513A (pt)
RU (1) RU2451684C2 (pt)
WO (1) WO2008116665A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
EP2072050A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
CA2724842A1 (en) * 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
MX336268B (es) 2011-07-29 2016-01-13 Toyama Chemical Co Ltd Compuesto de amidina o sal del mismo.
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
SG11201509650YA (en) 2013-05-24 2015-12-30 Iomet Pharma Ltd Slc2a transporter inhibitors
PL3356386T3 (pl) 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
WO2017097671A1 (de) * 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
JP2018536693A (ja) 2015-12-10 2018-12-13 バイエル・ファルマ・アクティエンゲゼルシャフト 睡眠関連呼吸障害を治療するためのTASK−1およびTASK−2チャネルの遮断薬としての2−フェニル−3−(ピペラジノメチル)イミダゾ[1,2−a]ピリジン誘導体
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
CN109640988A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
KR20190045216A (ko) 2016-09-16 2019-05-02 수미토모 케미칼 컴퍼니 리미티드 복소환 화합물 및 그것을 함유하는 유해 절족 동물 방제제
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR20210102347A (ko) * 2018-12-11 2021-08-19 사노피 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
KR20220112817A (ko) * 2019-12-10 2022-08-11 사노피 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법
CN114805237B (zh) * 2021-01-22 2026-04-21 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
CN113666926A (zh) * 2021-09-08 2021-11-19 桂林理工大学 一种便捷的2-苯基咪唑[1,2-a]吡啶与查尔酮的Michal加成反应

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
EP1218382B1 (de) * 1999-10-08 2004-01-28 Grünenthal GmbH Bicyclische imidazo-3-yl-aminderivate
DE60125980T2 (de) * 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
SE0100568D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands

Also Published As

Publication number Publication date
AU2008231977A1 (en) 2008-10-02
CA2682329A1 (en) 2008-10-02
US20100093697A1 (en) 2010-04-15
CN101663301A (zh) 2010-03-03
US8236818B2 (en) 2012-08-07
WO2008116665A1 (en) 2008-10-02
EP1974729A1 (en) 2008-10-01
RU2009134038A (ru) 2011-05-10
CN101663301B (zh) 2012-06-06
AU2008231977B2 (en) 2011-03-24
EP2144907A1 (en) 2010-01-20
KR20090122309A (ko) 2009-11-26
RU2451684C2 (ru) 2012-05-27
MX2009010429A (es) 2009-10-20
NZ579513A (en) 2011-03-31
CA2682329C (en) 2012-03-27
IL200804A0 (en) 2010-05-17
JP2010522224A (ja) 2010-07-01
WO2008116665A8 (en) 2008-12-11
KR101128140B1 (ko) 2012-03-23

Similar Documents

Publication Publication Date Title
BRPI0809346A2 (pt) Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
LTC2140867I2 (lt) Farmacinė kompozicija
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0715712A2 (pt) Composição farmacêutica
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
BRPI0810928A2 (pt) "composição farmacêutica"
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
BRPI0719393A2 (pt) Composição farmacêutica
DK2041139T3 (da) Farmaceutiske forbindelser
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
DK2120884T3 (da) Farmaceutisk sammensætning
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
PT2209464E (pt) Composição farmacêutica antimalárica
PT1850664E (pt) Formulação de cápsulas
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0816992A2 (pt) Derivado heterocíclico tricícloco, e, composição farmacêutica
BRPI0820198A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.